文献速递系统性红斑狼疮

基于分子内型的系统性红斑狼疮受试者对伊贝度胺的应答性

Responsiveness of systemic lupus erythematosus subjects to iberdomide based on molecular endotypes.
PubMed 文献 · Ann Rheum Dis · 2025-02-27

本研究基于2b期伊贝度胺试验(NCT03161483)中276例女性系统性红斑狼疮(SLE)受试者的全血RNA测序数据,通过基因集变异分析(GSVA)和K-means聚类识别出5种分子内型(A-E)。使用SLE应答指数4评估,对伊贝度胺的显著临床应答仅局限于内型C和E,不同内型中与应答相关的基因模块不同。

要点

  • 全血基因表达谱将276例女性SLE受试者分为5种分子内型(A-E),分子异常程度依次增加。
  • 对伊贝度胺的显著临床应答仅见于内型C和E,未见于其他内型。
  • 内型E应答者中最重要的治疗相关基因模块为Treg细胞、B细胞和干扰素。

核心结论

  • SLE受试者的分子谱识别出伊贝度胺在所有内型中均出现的药效学效应,以及与显著临床应答相关的内型中特定基因模块的改变。
  • 作者认为,基于基因表达的分子分型可能有助于富集临床试验中的治疗应答受试者,并监测治疗的药效学影响。

研究设计与样本

  • 本研究为2b期伊贝度胺试验(NCT03161483)的分子分析,纳入276例女性SLE受试者的全血样本,行RNA测序后使用32个信息基因模块进行基因集变异分析(GSVA),并以无监督K-means聚类按基线分子内型分类受试者。

主要发现

  • 对全血GSVA评分行K-means聚类得到5个患者亚组(内型A-E),分子异常增加提示免疫活性增强。
  • 使用SLE应答指数4判定,对伊贝度胺的显著临床应答仅局限于内型C和E。
  • 内型E应答者中最重要的治疗相关基因模块为Treg细胞、B细胞和干扰素。
  • 内型C中与应答相关的基因模块为未折叠蛋白、氧化磷酸化和无反应/活化T细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Iberdomide is a cereblon E3-ligase modulator that promotes proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) and was shown to be efficacious among subjects with generalised systemic lupus erythematosus (SLE). This study sought to identify baseline gene expression profiles of SLE subjects responsive to iberdomide and analyse the impact of this agent on gene expression. METHODS: Whole blood samples obtained from 276 female SLE subjects in the phase 2b iberdomide trial (NCT03161483) were assessed by RNA sequencing followed by gene set variation analysis (GSVA) using 32 informative gene modules. Unsupervised K-means clustering categorised subjects according to molecular endotypes at baseline. Each endotype was compared for treatment related gene expression changes. RESULTS: K-means clustering of GSVA scores from whole blood yielded 5 patient subsets (endotypes A-E) with increases in molecular abnormalities indicative of enhanced immune activity. Significant clinical responses to iberdomide, determined using the SLE Responder Index 4, were confined to endotypes C and E. The most important treatment related gene modules in responders in endotype E were Treg cells, B cells, and interferon, whereas unfolded proteins, oxidative phosphorylation and anergic/activated T cells were associated with responsiveness in endotype C. CONCLUSIONS: Molecular profiles of SLE subjects identified pharmacodynamic effects of iberdomide that occurred in all endotypes as well as changes in specific gene modules altered in endotypes associated with a significant clinical response. Thus, gene expression-based molecular profiling may be useful to enrich clinical trials for treatment-responsive subjects and also monitor the pharmacodynamic impact of therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bachali P, Daamen A, Korish S, et al. Responsiveness of systemic lupus erythematosus subjects to iberdomide based on molecular endotypes. Ann Rheum Dis. 2025. PMID: 40021405. doi:10.1016/j.ard.2025.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。